Cytokinetics Inc (CYTK) stock
CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
$51.65−1.52 (-2.86%)
Close on Nov 17, 2026Market cap $7.18BP/E –Yield –
Cytokinetics cash
Cash and short-term investments held at the end of each period.
Cytokinetics's cash was $1.70B at Jun 30, 2026. For fiscal 2025 it was $1.20B, up 0.0% from the year before. Over ten years it grew 26.8% a year on average. The highest annual figure on record is $1.20B in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.20B | 0.0% |
| FY2024 | Dec 31, 2024 | $1.20B | +83.1% |
| FY2023 | Dec 31, 2023 | $655.40M | -21.0% |
| FY2022 | Dec 31, 2022 | $829.30M | +33.0% |
| FY2021 | Dec 31, 2021 | $623.70M | +24.5% |
| FY2020 | Dec 31, 2020 | $501.00M | +87.1% |
| FY2019 | Dec 31, 2019 | $267.80M | +34.8% |
| FY2018 | Dec 31, 2018 | $198.70M | -30.4% |
| FY2017 | Dec 31, 2017 | $285.40M | +74.1% |
| FY2016 | Dec 31, 2016 | $163.90M | +46.9% |
| FY2015 | Dec 31, 2015 | $111.60M | +34.1% |
| FY2014 | Dec 31, 2014 | $83.20M | +3.7% |
| FY2013 | Dec 31, 2013 | $80.20M | +8.4% |
| FY2012 | Dec 31, 2012 | $74.00M | +51.0% |
| FY2011 | Dec 31, 2011 | $49.00M | -31.6% |
| FY2010 | Dec 31, 2010 | $71.64M | +180.3% |
| FY2009 | Dec 31, 2009 | $25.56M | -38.9% |
| FY2008 | Dec 31, 2008 | $41.82M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.70B | +70.0% |
| Q1 FY2026 | Mar 31, 2026 | $1.10B | 0.0% |
| Q4 FY2025 | Dec 31, 2025 | $1.20B | 0.0% |
| Q3 FY2025 | Sep 30, 2025 | $1.30B | 0.0% |
| Q2 FY2025 | Jun 30, 2025 | $1.00B | -28.6% |
| Q1 FY2025 | Mar 31, 2025 | $1.10B | +73.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.20B | +83.1% |
| Q3 FY2024 | Sep 30, 2024 | $1.30B | +134.4% |
| Q2 FY2024 | Jun 30, 2024 | $1.40B | +136.2% |
| Q1 FY2024 | Mar 31, 2024 | $634.30M | -10.0% |
| Q4 FY2023 | Dec 31, 2023 | $655.40M | -21.0% |
| Q3 FY2023 | Sep 30, 2023 | $554.70M | -36.1% |
| Q2 FY2023 | Jun 30, 2023 | $592.60M | +1.1% |
| Q1 FY2023 | Mar 31, 2023 | $704.40M | +15.7% |
| Q4 FY2022 | Dec 31, 2022 | $829.30M | +33.0% |
| Q3 FY2022 | Sep 30, 2022 | $867.66M | +81.7% |
| Q2 FY2022 | Jun 30, 2022 | $586.03M | +67.3% |
| Q1 FY2022 | Mar 31, 2022 | $608.97M | +43.1% |
| Q4 FY2021 | Dec 31, 2021 | $623.70M | +24.5% |
| Q3 FY2021 | Sep 30, 2021 | $477.64M | +16.4% |
| Q2 FY2021 | Jun 30, 2021 | $350.30M | +64.4% |
| Q1 FY2021 | Mar 31, 2021 | $425.58M | +92.8% |
| Q4 FY2020 | Dec 31, 2020 | $501.00M | +87.1% |
| Q3 FY2020 | Sep 30, 2020 | $410.26M | +147.1% |
| Q2 FY2020 | Jun 30, 2020 | $213.06M | +23.3% |
| Q1 FY2020 | Mar 31, 2020 | $220.71M | +25.0% |
| Q4 FY2019 | Dec 31, 2019 | $267.80M | +34.8% |
| Q3 FY2019 | Sep 30, 2019 | $166.04M | -21.1% |
| Q2 FY2019 | Jun 30, 2019 | $172.87M | -25.5% |
| Q1 FY2019 | Mar 31, 2019 | $176.62M | -29.8% |
| Q4 FY2018 | Dec 31, 2018 | $198.70M | -30.4% |
| Q3 FY2018 | Sep 30, 2018 | $210.31M | -31.8% |
| Q2 FY2018 | Jun 30, 2018 | $231.94M | -30.2% |
| Q1 FY2018 | Mar 31, 2018 | $251.45M | -2.2% |
| Q4 FY2017 | Dec 31, 2017 | $285.40M | +74.1% |
| Q3 FY2017 | Sep 30, 2017 | $308.20M | +257.1% |
| Q2 FY2017 | Jun 30, 2017 | $332.10M | – |
| Q1 FY2017 | Mar 31, 2017 | $257.20M | – |
| Q4 FY2016 | Dec 31, 2016 | $163.90M | – |
| Q3 FY2016 | Sep 30, 2016 | $86.30M | – |
See a number that looks wrong?